His scientific interests lie mostly in Surgery, Internal medicine, Clinical trial, Oncology and Glioma. The Surgery study which covers Lymphoma that intersects with Biopsy and Transplantation. His research on Internal medicine frequently links to adjacent areas such as Gastroenterology.
His Clinical trial research incorporates elements of Randomized controlled trial, Quality of life, Response assessment and Intensive care medicine. His study in Oncology is interdisciplinary in nature, drawing from both Magnetic resonance imaging and Chemotherapy. His research in Glioma intersects with topics in Cell growth, Cancer stem cell, Stem cell, Immunology and Cell cycle.
David Schiff mainly focuses on Internal medicine, Oncology, Surgery, Glioma and Cancer research. Internal medicine is a component of his Temozolomide, Bevacizumab, Radiation therapy, Chemotherapy and Clinical trial studies. David Schiff has researched Clinical trial in several fields, including Randomized controlled trial and Intensive care medicine.
His research on Oncology also deals with topics like
The scientist’s investigation covers issues in Internal medicine, Oncology, Glioblastoma, Radiation therapy and Temozolomide. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Glioma. His work investigates the relationship between Glioma and topics such as Brain tumor that intersect with problems in Quality of life.
His research integrates issues of Cancer, Immunotherapy, Clinical trial, Low-Grade Glioma and Newly diagnosed in his study of Oncology. His Radiation therapy research is multidisciplinary, incorporating elements of Tolerability and Oligodendroglioma. His work focuses on many connections between Temozolomide and other disciplines, such as Concomitant, that overlap with his field of interest in Hazard ratio.
Internal medicine, Oncology, Glioma, Temozolomide and Radiation therapy are his primary areas of study. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. His studies in Oncology integrate themes in fields like Clinical study design, Clinical trial, Astrocytoma, Oligodendroglioma and Immunotherapy.
His research in Glioma tackles topics such as Brain tumor which are related to areas like Multicenter study, Multicenter trial and Nuclear medicine. He has included themes like Survival rate, Magnetic resonance imaging and Survival analysis in his Temozolomide study. His work deals with themes such as Neuropathology and Low-Grade Glioma, which intersect with Radiation therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen.
Journal of Clinical Oncology (2009)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert;James J. Dignam;Terri S. Armstrong;Terri S. Armstrong;Jeffrey Scott Wefel.
The New England Journal of Medicine (2014)
Law as a Social System
Niklas Luhmann;Klaus A. Ziegert;Fatima Kastner;Richard Nobles.
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp;Eric T. Wong;Andrew A. Kanner;David Steinberg.
European Journal of Cancer (2012)
microRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
Yunqing Li;Fadila Guessous;Ying Zhang;Charles DiPierro.
Cancer Research (2009)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani.
Lancet Oncology (2015)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon;Karen L. Fink;Tom Mikkelsen;Timothy F. Cloughesy.
Journal of Clinical Oncology (2008)
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn.
Lancet Oncology (2011)
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
Leland Rogers;Igor Barani;Marc Chamberlain;Thomas J. Kaley.
Journal of Neurosurgery (2015)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
Susan M. Chang;Patrick Wen;Timothy Cloughesy;Harry Greenberg.
Investigational New Drugs (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: